Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: A 123I-ADAM SPECT study

Psychopharmacology

Volumn 189, Issue 2, 2006, Pages 145-153

  Catafau, Ana M ^a,b   Perez, Victor ^c   Plaza, Pedro ^b   Pascual, Juan Carlos ^c   Bullich, Santiago ^b   Suarez, Marina ^b   Penengo, Maria M ^b   Corripio, Iluminada ^c   Puigdemont, Dolors ^c   Danus, Monica ^b   Perich, Javier ^b   Alvarez, Enric ^c  

^a GLAXOSMITHKLINE   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL SANT PAU   (Spain)

Author keywords

123I ADAM SPECT; Major depression disorder; Occupancy; Paroxetine; Pharmacology; Serotonin transporter; Serotonin transporter availability

Indexed keywords

IODINE 123; PAROXETINE;

ADULT; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MATHEMATICAL MODEL; MEMBRANE TRANSPORT; MESENCEPHALON; MOLECULAR MODEL; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS; VOLUNTEER;

ADULT; BRAIN; CINANSERIN; CORPUS STRIATUM; DEPRESSIVE DISORDER; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MESENCEPHALON; MIDDLE AGED; PAROXETINE; RADIOLIGAND ASSAY; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 33750608063     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0540-y     Document Type: Article

References (34)

1. Ahonen A, Heikman P, Kauppinen T, Koskela A, Bergström K (2004) Serotonin transporter availability in drug free depression patients using a novel SERT ligand. Eur J Nucl Med 31:S227
2. Brett MA, Dierdorf HD, Zussman BD, Coates PE (1987) Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection. J Chromatogr 419:438-444
3. 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med 46:1301-1309
4. Cavanagh J, Patterson J, Pimlott S, Dewar D, Eersels J, Dempsey MF, Wyper D (2006) Serotonin transporter residual availability during long-term antidepressant therapy does not differentiate responder and nonresponder unipolar patients. Biol Psychiatry 59:301-308
5. Dahlstrom M, Ahonen A, Ebeling H, Torniainen P, Heikkila J, Moilanen I (2000) Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents. Mol Psychiatry 5:514-522
6. Dresel S, Mager T, Rossmüller B, Meisenzahl E, Hahn K, Möller H-J, Tatsch K (1999) In vivo effects of olanzapine on striatal dopamine D2/D3 receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. Eur J Nucl Med 26:862-868
7. 123I]ADAM: a SPECT validation study. Eur J Nucl Med Mol Imaging 32:1329-1336
8. Figueras G, Pérez V, San Martino O, Álvarez E, Grupo de Trastornos Afectivos, Artigas F (1999) Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Biol Psychiatry 46:518-524
9. Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R (1998) Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia. Psychopharmacology 135:119-126
10. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
11. 123I]ADAM. J Neural Transm 113(5):659-670
12. 11C](+)McN5652. Biol Psychiatry 51:715-722
13. Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J Psychiatry 156:286-293
14. Knable MB, Heinz A, Raedler T, Weinberger DR (1997) Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res 75:91-101
15. 11C]McN 5652. Psychopharmacology 164:341-348
16. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, Van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB (2004) Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 56:497-502
17. 123I-β-CIT pharmacological characterization of brain uptake in nonhuman primates. Synapse 13(4):295-309
18. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS (1998) Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane and single photon emission computed tomography. Biol Psychiatry 44(11):1090-1098
19. 11C]DASB PET imaging study. Am J Psychiatry 158:1843-1849
20. 11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835
21. Meyer JH, Houle S, Sagrati S, Carella A, Hussey D, Ginovart N, Goulding V, Kennedy J, Wilson AA (2004b) Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61:1271-1279
22. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med 46:973-977
23. Nyberg S, Chou YH, Halldin C (2002) Saturation of striatal D2 dopamine receptors by clozapine. Int J Neuropsychopharmacol 5(1):6-11
24. Normann C, Horn M, Hummel B, Grunze H, Walden J (2004) Paroxetine in major depression correlating plasma concentration and clinical response. Pharmacopsychiatry 37(3):123-126
25. Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40:288-295
26. Parsey RV, Hastings RS, Oquendo MA, Huang Y, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V, Mann JJ (2006) Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 163:52-58
27. Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, Pozzera A, Deecke L, Podreka I, Brücke T (1995) β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm 100:247-256
28. Rits (1964) Declaration of Helsinki. Recommendations guiding doctors in clinical research. World Med J 11:281
29. Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT, Berman RM, Vythilingam M, Kugaya A, Baldwin RM, Seibyl JP, Charney D, Innis RB (2005) Sex differences in diencephalons serotonin transporter availability in major depression. Biol Psychiatry 59:40-47
30. Stockmeier CA (2003) Involvement of serotonin in depression: evidence from post-mortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res 37:357-373
31. Talvik M, Nordström A-L, Larsen N-E, Jucaite A, Cervenka S, Halldin C, Farde L (2004) A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology 175:148-153
32. Tauscher J, Küfferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brücke T, Kasper S (1999a) In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 141:175-181
33. Tauscher J, Pirker W, De Zwaan M, Asenbaum S, Brücke T, Kasper S (1999b) In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol 9:177-179
34. Williams RB (1994) Neurobiology, cellular and molecular biology, and psychosomatic medicine. Psychosom Med 56:308-315